Phathom Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Phathom Pharmaceuticals, Inc. (PHAT)
Last phathom pharmaceuticals, inc. earnings: 3/19 08:31 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Phathom Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Execution and Performance Drivers Delivered 217% year-over-year revenue growth in 2025, reaching the high end of guidance through a transformational shift toward a GI-focused sales strategy. Achieved a 50% reduction in quarterly cash operating expenses by Q4 2025, demonstrating disciplined cost management while maintaining commercial momentum. Successfully penetrated the gastroenterology market, with over 1.1 million total prescriptions filled and a high percentage of GIs having already initiated therapy. Utilized a 'covered prescription' model to drive core revenue while leveraging 'cash pay' options to improve physician perception of access and ease of prescribing. Implemented an 'adoption ladder' framework to transition physicians from trial users to consistent adopters, resulting in over 2,000 physicians reaching high-frequency writing tiers. Optimized the sales organization to a nearly ful
Show less
Read more
Impact Snapshot
Event Time:
PHAT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHAT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHAT alerts
High impacting Phathom Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
PHAT
News
- Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here's Why [Yahoo! Finance]Yahoo! Finance
- Why Phathom Pharmaceuticals (PHAT) Is Up 13.2% After Guiding To 2026 Operating Profitability And Narrower Losses [Yahoo! Finance]Yahoo! Finance
- Phathom Pharmaceuticals (PHAT) had its price target raised by Guggenheim from $20.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- Phathom Pharmaceuticals (PHAT) was given a new $28.00 price target by Stifel Nicolaus.MarketBeat
- Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance [Yahoo! Finance]Yahoo! Finance
PHAT
Earnings
- 2/26/26 - Beat
PHAT
Sec Filings
- 3/3/26 - Form 4
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- PHAT's page on the SEC website